I asked the Therapeutic Goods Administration (TGA) about the way they test the vaccines they market as “safe and effective” and mandate for children. I already knew the answer – I was just trying to get a clear statement so the public could understand just how much of a farce the “testing” process truly is.
The representatives danced around the questions, trying to be as confusing as possible.
The TGA does not actually test vaccines. Instead, they rely on safety and efficacy data provided by the manufacturer. This data is based on the company’s own testing of its own product. If the manufacturer (drug company) says it’s safe, the TGA gives it a stamp of approval.
Furthermore, we know that drug companies are not using the correct process for testing new vaccines or drugs. The standard should be to test the new product against an inert saline placebo. Instead, they use an existing vaccine or drug as the control.
This means our vaccines have been tested against products already known to have side effects – and approved as long as the side effects of the new drug are no worse than those of the old one. This is criminal behaviour.
Peer-reviewed papers have shown that the testing on the COVID-19 vaccines was fraudulent. It’s not good enough for the TGA to claim they review documentation carefully; the Pfizer testing scandal proves they do nothing of the sort.
— Senate Estimates | February 2026
Transcript
Senator ROBERTS: Thank you. Question on notice 3215, I asked about a report from the American Food and Drug Administration’s Center for Biologics Evaluation and Research, which stated perfectly clearly that there were 10 paediatric deaths were linked to the COVID jabs. I asked if you had supporting data in Australia. Your reply referenced reported paediatric deaths after COVID jabs and found:
… causality has not been established for those in children.
How hard did you look? Were there autopsies, an independent medical board reviewing the medical file for each, deciding that, no, the jab did not cause the death? What was the process you engaged?
Prof. Lawler: Thanks for that question. I will ask Dr Dascombe to comment on the process that we’ve explained previously around our pharmacovigilance that is designed and delivers on our analysis of adverse events, including deaths that occurred temporally following vaccination. I would just highlight as well that, as previously stated regarding the identified paediatric deaths following vaccines, I mentioned that we’d not been provided with information regarding those deaths. I believe that still to be the case. The claim that there had been these deaths that had been causally linked to vaccination has not, to my knowledge, been substantiated. But, again, if that is not the case, I’d be very prepared to correct the record. Dr Dascombe can comment on the work that we undertake to respond to reported adverse events.
Dr Dascombe: Every death that’s reported to the TGA following any vaccination is reviewed to determine whether a regulatory response is necessary based on the weight of available evidence. It’s important to note the TGA does not determine causes of death. This is determined by coroners and treating doctors, as we’ve explained before, and the TGA has no role in overruling causes of death that are included on a person’s death certificate. The causality assessment that’s done by the TGA is primarily concerned with the relationship between the vaccine and the adverse event, rather than the outcome itself, and it’s undertaken as a regulatory process with the intention of appraising risk-benefit balance at a population level for that specific vaccine under Australia’s regulatory framework.
Senator ROBERTS: Do you do autopsies?
Dr Dascombe: As I just said, the TGA has no role in the determination of cause of death for individuals.
Senator ROBERTS: That was my understanding too. In 2026, the United States’ Department of Health and Human Services removed rotavirus, COVID-19, influenza, meningococcal disease, hepatitis A and hepatitis B from the schedule. Australia still requires rotavirus, hepatitis-B and meningococcal ACWY. Is the United States’ FDA wrong, or are you wrong on the risk-benefit of those vaccines?
Dr Peatt: I can’t comment on the US, but, as outlined by my colleagues Professor Lawler and Associate Professor Katherine Gibney, the four vaccines to be made available on the National Immunisation Program requires a very high bar. It includes TGA assessment of the safety and efficacy of the vaccine but also undergoes ATAGI assessment for the clinical effectiveness. It then goes through Pharmaceutical Benefits Advisory Committee assessment and then needs to be approved by government for funding. There’s also ongoing monitoring by ATAGI and TGA, who constantly assess whether those vaccines are appropriate for the Australian community.
Prof. Lawler: If I may very quickly add—I think it’s really important to note that one of the great strengths of Australia’s regulatory system and, indeed, of ATAGI is that we do make decisions based upon the nature of disease patterns in Australia. Every country will take its own approach to immunisation schedules. They rely on the evidence and rely on the demography and the epidemiology in their own areas. If we were simply to make decisions based upon what other regulators say, then I can almost guarantee that I’d be back at the next estimates answering questions around why we weren’t making our own sovereign decisions. So I think it’s important to note that the vaccination schedule is appropriate to the Australian context because of the evidence upon which it relies.
